Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00806065 · ClinicalTrials.gov registry record · Phase 1

Study of ENMD-2076 in Patients With Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by CASI Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT00806065 is a Phase 1 study of Multiple Myeloma that has completed, run by CASI Pharmaceuticals. The registered enrollment target is 13 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00806065, a Phase 1 study of Multiple Myeloma, has completed, sponsored by CASI Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG ENMD-2076

Study Locations (1)

Indiana

  • Indiana University Melvin and Bren Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2008-12
Est. Completion 2012-01
Phase Phase 1

Sponsor

CASI Pharmaceuticals

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00806065

The ClinicalTrials.gov registry entry for NCT00806065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is CASI Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which ENMD-2076 is the first listed.

NCT00806065 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00806065 about?

NCT00806065 is a clinical study titled "Study of ENMD-2076 in Patients With Multiple Myeloma". Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.

What is the current status of trial NCT00806065?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-12. Estimated completion is 2012-01.

What conditions does trial NCT00806065 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00806065?

The interventions under investigation include: ENMD-2076 (DRUG).

Who is sponsoring clinical trial NCT00806065?

This trial is sponsored by CASI Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00806065 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.